ARMP Should I Buy

ARMP is not a good buy right now for a Beginner long-term investor with $50k–$100k who is impatient for results. The stock is a high-volatility clinical-stage biotech with deteriorating revenue trends, no fresh news catalyst this week, no proprietary buy signals today, and options positioning that leans defensive (put-heavy open interest). The pre-market pop to ~7.05 is also already pushing above nearby resistance, which increases the odds of a near-term pullback rather than a clean low-risk long-term entry.

Trend/price action: ARMP is up sharply in pre-market (~7.05, +6.98%) and is trading above R2 (6.931), meaning it’s already breaking into an extended area versus recent pivot levels. Momentum: MACD histogram is negative (-0.0293) but contracting, suggesting downside momentum is easing, not that a strong uptrend is confirmed. RSI(6) ~59.7 is neutral-to-slightly-bullish but not overbought. Moving averages are converging, which typically signals a transition phase rather than a confirmed trend. Key levels: Pivot 6.214; support S1 5.771 / S2 5.497; resistance R1 6.657 / R2 6.931. With pre-market above R2, the next decision point is whether it can hold above ~6.93; failing that often leads to a retest of ~6.66 or ~6.21.